Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Clin Pharmacol Ther. 2021 Jan 7;109(6):1639–1647. doi: 10.1002/cpt.2148

Figure 1.

Figure 1

Comparison of model accuracy between the (a) base pharmacokinetic (PK) model and the (b) full model that includes weight, serum albumin (ALB), neutrophil CD64 activity ratio (nCD64), antibody to infliximab (ATI), and erythrocyte sedimentation rate (ESR) as covariates of drug clearance. With the full model, the improved predicted accuracy is depicted as the observed drug concentrations (dots) and individual predicted curves (dashed-lines) are in closer proximity to the population predicted PK curve (solid line) when compared with the base model for each representative patient.1–4